SCHEMBL5898100

SCHEMBL5898100

CCCC[C](CCC)C(CC)CCC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 7/20 0.40
MAPK1 P28482 1/20 0.40
CA1 P00915 4/20 0.39
CHRM1 P11229 1/20 0.36
AKR1A1 P14550 1/20 0.36
CHRM3 P20309 1/20 0.36
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
ADRA1A P35348 1/20 0.36
HRH1 P35367 1/20 0.36
DRD3 P35462 1/20 0.36
SLC6A3 Q01959 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CYP3A4 P08684 2/20 0.34
TSHR P16473 2/20 0.34
NFKB1 P19838 2/20 0.34
NPSR1 Q6W5P4 2/20 0.34
ALDH1A1 P00352 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16975161 0.86 CA2 (0.40) CA2MAPK1CA1CHRM1AKR1A1
SCHEMBL8927877 0.86 CA2 (0.54) CA2MAPK1CA1TDP1TSHR
SCHEMBL1983515 0.86 CA2 (0.54) CA2MAPK1CA1TDP1CYP3A4
SCHEMBL7765839 0.85 CHRM1 (0.42) CA2MAPK1CA1CHRM1AKR1A1
SCHEMBL5483393 0.83 CA2 (0.42) CA2TSHRALDH1A1
SCHEMBL10583487 0.83 CA2 (0.42) CA2MAPK1CA1
SCHEMBL10456170 0.81 CHRM1 (0.39) CA2MAPK1CA1CHRM1AKR1A1
SCHEMBL16098245 0.81 CA2 (0.43) CA2MAPK1CA1ALDH1A1CES2
SCHEMBL7904735 0.81 CA2 (0.43) CA2MAPK1CA1CHRM1AKR1A1
SCHEMBL10535669 0.80 CA2 (0.39) CA2MAPK1CA1CES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0236215-B1 2,2'-DIFLUORO-4-ALKOXY-4'-HYDROXY BIPHENYLS AND THEIR DERIVATIVES, THEIR PRODUCTION PROCESS AND THEIR USE IN LIQUID CRYSTAL DISPLAY DEVICES COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 1990-01-10 EP claimed
CN-115309734-A Multi-source heterogeneous data processing method for transformer substation 广东电网有限责任公司东莞供电局 2022-11-08 CN disclosed
EP-2958883-A1 CYCLOHEXENONE COMPOSITIONS AND PROCESS FOR MAKING THEREOF Golden Biotechnology Corporation (US) 2015-12-30 EP disclosed
WO-2014130618-A1 CYCLOHEXENONE COMPOSITIONS AND PROCESS FOR MAKING THEREOF GOLDEN BIOTECHNOLOGY CORPORATION (US) 2014-08-28 WO disclosed
US-7074927-B2 Heterocyclic amines having central nervous system activity PHARMACIA & UPJOHN COMPANY (US) 2006-07-11 US disclosed
US-20050107378-A1 Heterocyclic amines having central nervous system activity ROMERO ARTHUR G (US) 2005-05-19 US disclosed
US-5077287-A Treating infectious diseases in man and animals ELI LILLY AND COMPANY (US) 1991-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107378-A1 Heterocyclic amines having central nervous system activity CNR1, CNR2, NPY2R CA2 1393/4885MAPK1 618/4885CA1 3238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.